BPC-157 vs TB4-Frag (TBF)
A side-by-side research comparison of BPC-157 and TB4-Frag (TBF) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 | TB4-Frag (TBF) |
|---|---|---|
| Full name | Body Protection Compound-157 | Thymosin Beta-4 Fragment |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Upregulates growth factor expression including VEGF and promotes angiogenesis, modulates nitric oxide system, and interacts with the dopaminergic system. | Retains the actin-sequestering motif of full TB-4, promoting cell migration, angiogenesis, and reduction of inflammation at injury sites. The shorter sequence may offer improved bioavailability and targeted tissue penetration. |
| Molecular weight | 1419.53 Da | ~1,200-1,800 Da (fragment) |
| Half-life | ~4 hours | ~2-4 hours |
| Bioavailability | Variable; oral and injectable forms available | High subcutaneous absorption |
| Typical dose | 250-500 mcg per dose | 200-750 mcg per dose |
| Frequency | 1-2x daily | Daily or every other day |
| Route | Subcutaneous injection (or oral capsules) | Subcutaneous injection |
BPC-157 reported benefits
- Accelerated tendon and ligament healing
- Gut lining protection and repair
- Neuroprotective effects
- Anti-inflammatory properties
- Muscle tear recovery
TB4-Frag (TBF) reported benefits
- Wound and tissue healing
- Reduced inflammation
- Potential improved tissue penetration vs full TB-4
- Support for tendon and muscle repair
- Angiogenesis promotion
Related comparisons
Research and educational reference only. Not medical advice.